164 related articles for article (PubMed ID: 22922531)
1. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL; Sill MW; Lankes HA; Fader AN; Finkler NJ; Hoffman JS; Rose PG; Sutton GP; Drescher CW; McMeekin DS; Hu W; Deavers M; Godwin AK; Alpaugh RK; Sood AK
Gynecol Oncol; 2012 Dec; 127(3):538-43. PubMed ID: 22922531
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.
Dizon DS; Blessing JA; McMeekin DS; Sharma SK; Disilvestro P; Alvarez RD
J Clin Oncol; 2009 Jul; 27(19):3104-8. PubMed ID: 19451430
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Twardowski P; Stadler WM; Frankel P; Lara PN; Ruel C; Chatta G; Heath E; Quinn DI; Gandara DR
Urology; 2010 Oct; 76(4):923-6. PubMed ID: 20646741
[TBL] [Abstract][Full Text] [Related]
9. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
Mackay HJ; Buckanovich RJ; Hirte H; Correa R; Hoskins P; Biagi J; Martin LP; Fleming GF; Morgan R; Wang L; Polintan R; Oza AM
Gynecol Oncol; 2012 Apr; 125(1):136-40. PubMed ID: 22138373
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
11. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Leighl NB; Raez LE; Besse B; Rosen PJ; Barlesi F; Massarelli E; Gabrail N; Hart LL; Albain KS; Berkowitz L; Melnyk O; Shepherd FA; Sternas L; Ackerman J; Shun Z; Miller VA; Herbst RS
J Thorac Oncol; 2010 Jul; 5(7):1054-9. PubMed ID: 20593550
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
18. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study.
Covens A; Brunetto VL; Markman M; Orr JW; Lentz SS; Benda J;
Gynecol Oncol; 2003 Jun; 89(3):470-4. PubMed ID: 12798713
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
